Dogwood Therapeutics has strengthened its financial position by converting $19.5 million in debt to equity, removing all existing debt from its balance sheet and improving its investment profile.
Virios Therapeutics and Wex Pharmaceuticals have merged in an all-stock transaction, creating Dogwood Therapeutics (NASDAQ: DWTX), focused on clinical development of Halneuron®, IMC-1, and IMC-2.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.